Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Is randomisation of clinical trials still the gold standard?

Presentation of case/condition: Review of novel agents licensed for use in the 21st century

Date

28 Sep 2019

Session

Is randomisation of clinical trials still the gold standard?

Topics

Cytotoxic Therapy;  Bioethical Principles and GCP;  Immunotherapy;  Patient Education and Advocacy

Tumour Site

Presenters

Udai Banerji

Authors

U. Banerji

Author affiliations

  • Drug Development Unit  , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Why we need randomization

Presenter: Urania Dafni

Session: Is randomisation of clinical trials still the gold standard?

Resources:

Slides

Webcast

The voice of the regulator (EMA)

Presenter: Francesco Pignatti

Session: Is randomisation of clinical trials still the gold standard?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.